Condition: Breast Cancer Stage IV · Sponsor: SOLTI Breast Cancer Research Group
This is an open-label, single arm, non-randomized, multicenter phase II study for the identification of predictive biomarkers of sacituzumab govitecan benefit and the understanding of key resistance mechanisms in HR+/HER2- advanced/metastatic breast cancer patients
This description comes directly from the study's public registry record.
Mariana Paes Dias, PhD · 0034 609 384 751 · mariana.paes@gruposolti.org
Fernando Salvador, PhD · 0034 616 194 478 · fernando.salvador@gruposolti.org
Always discuss trial participation with your own doctor first.
| ICO Badalona | Badalona, Barcelona, Spain | Not Yet Recruiting |
| ICO Hospitalet | L'Hospitalet de Llobregat, Barcelona, Spain | Not Yet Recruiting |
| Hospital Universitari Vall d'Hebrón | Barcelona, Spain | Not Yet Recruiting |
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| HU Clínico San Cecilio | Granada, Spain | Not Yet Recruiting |
| Fundación Jiménez Díaz | Madrid, Spain | Not Yet Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Not Yet Recruiting |
| Hospital Sant Joan de Reus | Reus, Spain | Recruiting |
| Hospital Universitario Virgen del Rocio | Seville, Spain | Not Yet Recruiting |
| Hospital Clínico de Valencia | Valencia, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06236269